Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Children's Hospital Medical Center, Cincinnati
Participants who meet study eligibility will receive or continue to receive blinatumomab by continuous IV infusion for 28 days and also receive pembrolizumab (by IV infusion over 30 minutes) on day 12 of cycle 1 and day 5 of cycle 2. One cycle lasts 35 days and patients will receive 2 cycles of therapy.
Age
1–40
Sex
ALL
Healthy volunteers
Not accepted
